RACAP is a financial services firm specializing in capital allocation strategies and portfolio management solutions. The company leverages advanced analytics and market insights to optimize investment decisions for its clients.

RA Capital Management® (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital® to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization.At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes in a continual effort to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides RA Capital’s investment team and portfolio companies with strategic intelligence, market research, and other resources. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability.

Vor Biopharma

Wave Life Sciences

Shockwave Medical

G1 Therapeutics

Global Blood Therapeutics

Graphite Bio

Imara

Solid Biosciences

Spero Therapeutics

Stoke Therapeutics

Vaxcyte

T2 Biosystems

Tenaya Therapeutics

Crinetics Pharmaceuticals

Cybin

Cyteir Therapeutics

Day One Biopharmaceuticals

Nimbus Therapeutics

Novavax

Pardes Biosciences

Point Biopharma

Janux Therapeutics

Kala Pharmaceuticals

KalVista Pharmaceuticals

Legend Biotech

Lyra Therapeutics

Moderna

Natera

Acrivon Therapeutics

Invivyd

Agile Therapeutics

Akouos

AN2 Therapeutics

Arcutis Biotherapeutics

Ardelyx

Ascendis Pharma

Third Harmonic Bio

Verve Therapeutics

Athersys

Dice Therapeutics

FORMA Therapeutics

Biohaven Pharmaceutical

Black Diamond Therapeutics

Bluebird Bio

Blueprint Medicines

Bolt Biotherapeutics

Bristol-Myers Squibb

Century Therapeutics

Cerevel Therapeutics

Nautilus Biotechnology

New Amsterdam Pharma

Coherus Biosciences

Sierra Oncology

EyePoint Pharmaceuticals

RA Capital Management

RACAP

COM:RACAP

RACAP

Analysis Not Available